Ida Aringer
Medical University of Graz
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ida Aringer.
The Journal of Allergy and Clinical Immunology | 2016
Katharina Jandl; Elvira Stacher; Zoltán Bálint; Eva M. Sturm; Jovana Maric; Miriam Peinhaupt; Petra Luschnig; Ida Aringer; Alexander Fauland; Viktoria Konya; Sven-Erik Dahlén; Craig E. Wheelock; Dagmar Kratky; Andrea Olschewski; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Background Prostaglandin (PG) D2 is an early-phase mediator in inflammation, but its action and the roles of the 2 D-type prostanoid receptors (DPs) DP1 and DP2 (also called chemoattractant receptor–homologous molecule expressed on TH2 cells) in regulating macrophages have not been elucidated to date. Objective We investigated the role of PGD2 receptors on primary human macrophages, as well as primary murine lung macrophages, and their ability to influence neutrophil action in vitro and in vivo. Methods In vitro studies, including migration, Ca2+ flux, and cytokine secretion, were conducted with primary human monocyte-derived macrophages and neutrophils and freshly isolated murine alveolar and pulmonary interstitial macrophages. In vivo pulmonary inflammation was assessed in male BALB/c mice. Results Activation of DP1, DP2, or both receptors on human macrophages induced strong intracellular Ca2+ flux, cytokine release, and migration of macrophages. In a murine model of LPS-induced pulmonary inflammation, activation of each PGD2 receptor resulted in aggravated airway neutrophilia, tissue myeloperoxidase activity, cytokine contents, and decreased lung compliance. Selective depletion of alveolar macrophages abolished the PGD2-enhanced inflammatory response. Activation of PGD2 receptors on human macrophages enhanced the migratory capacity and prolonged the survival of neutrophils in vitro. In human lung tissue specimens both DP1 and DP2 receptors were located on alveolar macrophages along with hematopoietic PGD synthase, the rate-limiting enzyme of PGD2 synthesis. Conclusion For the first time, our results show that PGD2 markedly augments disease activity through its ability to enhance the proinflammatory actions of macrophages and subsequent neutrophil activation.
British Journal of Pharmacology | 2015
Viktoria Konya; Jovana Maric; Katharina Jandl; Petra Luschnig; Ida Aringer; I Lanz; Wolfgang Platzer; Anna Theiler; Thomas Bärnthaler; Robert Frei; Gunther Marsche; L M Marsh; Andrea Olschewski; Irmgard Th. Lippe; Akos Heinemann; Rufina Schuligoi
Pulmonary vascular dysfunction is a key event in acute lung injury. We recently demonstrated that PGE2, via activation of E‐prostanoid (EP)4 receptors, strongly enhances microvascular barrier function in vitro. The aim of this study was to investigate the beneficial effects of concomitant EP4 receptor activation in murine models of acute pulmonary inflammation.
British Journal of Pharmacology | 2015
Konya; Jovana Maric; Katharina Jandl; Petra Luschnig; Ida Aringer; I Lanz; Wolfgang Platzer; Anna Theiler; Thomas Bärnthaler; Robert Frei; Gunther Marsche; L M Marsh; A Olschewski; I.Th. Lippe; Akos Heinemann; Rufina Schuligoi
Pulmonary vascular dysfunction is a key event in acute lung injury. We recently demonstrated that PGE2, via activation of E‐prostanoid (EP)4 receptors, strongly enhances microvascular barrier function in vitro. The aim of this study was to investigate the beneficial effects of concomitant EP4 receptor activation in murine models of acute pulmonary inflammation.
Pediatric Nephrology | 2017
Katharina Artinger; Alexander H. Kirsch; Ida Aringer; Foteini Moschovaki-Filippidou; Philipp Eller; Alexander R. Rosenkranz; Kathrin Eller
The role of innate and adaptive immune cells in the experimental model of nephrotoxic serum nephritis (NTS) has been rigorously studied in recent years. The model is dependent on kidney-infiltrating T helper (TH) 17 and TH1 cells, which recruit neutrophils and macrophages, respectively, and cause sustained kidney inflammation. In a later phase of disease, regulatory T cells (Tregs) infiltrate the kidney in an attempt to limit disease activity. In the early stage of NTS, lymph node drainage plays an important role in disease initiation since dendritic cells present the antigen to T cells in the T cell zones of the draining lymph nodes. This results in the differentiation and proliferation of TH17 and TH1 cells. In this setting, immune regulatory cells (Tregs), namely, CCR7-expressing Tregs and mast cells (MCs), which are recruited by Tregs via the production of interleukin-9, exert their immunosuppressive capacity. Together, these two cell populations inhibit T cell differentiation and proliferation, thereby limiting disease activity by as yet unknown mechanisms. In contrast, the spleen plays no role in immune activation in NTS, but constitutes a place of extramedullary haematopoiesis. The complex interactions of immune cells in NTS are still under investigation and might ultimately lead to targeted therapies in glomerulonephritis.
PLOS ONE | 2015
Katharina Artinger; Alexander H. Kirsch; Ida Aringer; Corinna Schabhüttl; Alexander R. Rosenkranz; Philipp Eller; Elena Rho; Kathrin Eller
Background The spleen has been implicated in the pathogenesis of immune-complex glomerulonephritis by initiating and resolving adaptive immune responses. Thus, we aimed to evaluate the role of the spleen in experimental nephrotoxic serum nephritis (NTS). Methods In order to accelerate the disease, animals were subjected to NTS by preimmunizing male C57BL/6J mice with rabbit IgG three days before injecting the rabbit anti-glomerular basement antiserum, or were immunized only. A group underwent splenectomy before NTS induction. Results We observed enlargement of the spleen with a maximum at 14 days after NTS induction or immunization only. Splenectomized mice were found to develop albuminuria and renal histological changes comparable to sham-operated controls. Nevertheless, anaemia was aggravated in mice after splenectomy. During the course of NTS, we detected CD41+ megakaryocytes and Ter119+ erythroid precursor cells in the spleen of mice with NTS and of immunized mice. Ter119+Cxcr4+ cells and the binding partner Cxcl12 increased in the spleen, and decreased in the bone marrow. This was accompanied by a significant systemic increase of interferon-gamma in the serum. Conclusions In summary, splenectomy does not influence the course of NTS per se, but is involved in concomitant anaemia. Extramedullary haematopoiesis in the spleen is probably facilitated through the migration of Cxcr4+ erythroid precursor cells from the bone marrow to the spleen via a Cxcl12 gradient and likely arises from the suppressive capacity of chronic inflammation on the bone marrow.
American Journal of Physiology-renal Physiology | 2018
Ida Aringer; Katharina Artinger; Alexander H. Kirsch; Corinna Schabhüttl; Katharina Jandl; Thomas Bärnthaler; Agnes Mooslechner; Sereina A. Herzog; Moritz Uhlig; Andrijana Kirsch; Saša Frank; Miriam C. Banas; Marion J. Pollheimer; Philipp Eller; Alexander R. Rosenkranz; Akos Heinemann; Kathrin Eller
Prostaglandin E2 (PGE2) signaling is known to modulate inflammation and vascular resistance. Receptors of PGE2 [E-type prostanoid receptors (EP)] might be an attractive pharmacological target in immune-mediated diseases such as glomerulonephritis. We hypothesized that selective EP4 antagonism improves nephrotoxic serum nephritis (NTS) by its anti-inflammatory properties. Mice were subjected to NTS and treated with the EP4 antagonist ONO AE3-208 (10 mg·kg body wt-1·day-1] or vehicle starting from disease initiation. In one set of experiments, treatment was started 4 days after NTS induction. Tubular epithelial cells were evaluated in vitro under starving conditions. EP4 antagonist treatment significantly improved the NTS phenotype without affecting blood pressure levels. Remarkably, the improved NTS phenotype was also observed when treatment was started 4 days after NTS induction. EP4 antagonism decreased tubular chemokine (C-X-C motif) ligand ( Cxcl) 1 and Cxcl-5 expression and thereby subsequently reduced interstitial neutrophil infiltration into the kidney. In vitro, tubular epithelial cells increasingly expressed Cxcl-5 mRNA and Cxcl-5 protein when treated with PGE2 or an EP4 agonist under starving conditions, which was blunted by EP4 antagonist treatment. Together, EP4 antagonism improves the NTS phenotype, probably by decreasing mainly Cxcl-5 production in tubular cells, thereby reducing renal neutrophil infiltration.
International Journal of Endocrinology | 2017
Bianca Frauscher; Katharina Artinger; Alexander H. Kirsch; Ida Aringer; Foteini Moschovaki-Filippidou; Máté Kétszeri; Corinna Schabhüttl; Peter P. Rainer; Albrecht Schmidt; Tatjana Stojakovic; Astrid Fahrleitner-Pammer; Alexander R. Rosenkranz; Philipp Eller; Kathrin Eller
Chronic kidney disease (CKD) is associated with mineral and bone disorder (MBD), which is the main cause of the extensively increased cardiovascular mortality in the CKD population. We now aimed to establish a new murine experimental CKD-MBD model. Dilute brown non-Agouti (DBA/2) mice were fed with high-phosphate diet for 4 (HPD4) or 7 (HPD7) days, then with standard chow diet (SCD) and subsequently followed until day 84. They were compared to DBA/2 mice maintained on SCD during the whole study period. Both 4 and 7 days HPD-fed mice developed phosphate nephropathy with tubular atrophy, interstitial fibrosis, decreased glomerular filtration rate, and increased serum urea levels. The abdominal aorta of HPD-treated mice showed signs of media calcification. Histomorphometric analysis of HPD-treated mice showed decreased bone volume/tissue volume, low mineral apposition rate, and low bone formation rate as compared to SCD-fed mice, despite increased parathyroid hormone levels. Overall, the observed phenotype was more pronounced in the HPD7 group. In summary, we established a new, noninvasive, and therefore easy to perform reproducible CKD-MBD model, which showed media calcification, secondary hyperparathyroidism, and low-turnover bone disease.
Nephrology Dialysis Transplantation | 2018
Agnes Mooslechner; Alexander H. Kirsch; Katharina Artinger; Ida Aringer; Foteini Moschovaki-Filippidou; Corinna Schabhüttl; Alexander R. Rosenkranz; Kathrin Eller
Nephrology Dialysis Transplantation | 2016
Katharina Artinger; Alexander H. Kirsch; Daniel J. Cooper; Ida Aringer; Corinna Schabhüttl; Philip Eller; PeterJ Lane; Alexander R. Rosenkranz; Kathrin Eller
Nephrology Dialysis Transplantation | 2016
Katharina Artinger; Alexander H. Kirsch; Ida Aringer; Corinna Schabhuettl; Michaela Krainer; Philipp Eller; Alexander R. Rosenkranz; Kathrin Eller